Find a Tender
complete
Official procurement procedure
BH_NonClinical_Pharmacy_Car-T
No classification published
Location not published
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: Barts Health NHS Trust: "BH_NonClinical_Pharmacy_Car-T". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
| Contracting Authority | Barts Health NHS Trust | Scope & Categories | Not published | Submission Window | complete No deadline published |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | Not published |
Bidder Intelligence · Authority Profile: Barts Health NHS Trust
Market Analytics
Derived from OCDS awards & bid statistics
Published history for Barts Health NHS Trust. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Average Price Reduction
Not availableInsufficient comparable data
Competition Density
5Bids / Report
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate availablePayment Terms
Check noticePublished terms
Coverage: 1 active published awards; 1 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Price reduction compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityBarts Health NHS Trust | Procedure methodNot published | Procurement categoryNot published |
Statuscomplete | Framework / DPSNot published | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published26 Nov 2025, 09:46 GMT | Last source update26 Nov 2025, 09:46 GMT | Recurring procurementNot published |
ClassificationNot published | ||
Delivery areaLocation not published | ||
OCIDocds-h6vhtk-05e8d3 | ||
What is being bought
CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a new personalised immunotherapy treatment where a patient’s T cells are genetically modified to target cancer cells.
The proposed contractor, Bristol Myers Squibb, will supply privately developed CAR T products
At the time of writing it is only offered at 8 sites across the UK.
The proposed contract is for 5 years with the option to extend by up to a further 5 years. The contract does not commit the Trust to place a minimum or any Order.
The price paid to the supplier with be capped at NICE / NHS England approved list prices.
What changed
From the official release history
- Status changed to complete
26 Nov 2025, 09:46 GMT - Official notice release published
26 Nov 2025, 09:46 GMT - Buyer information updated
26 Nov 2025, 09:46 GMT
Lots and requirements (1)
Published by the contracting authority
- Lot 1 · #1Individual lot title not publishedcompletePublished valueNot publishedThe source published no individual title or description for this lot.Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Procedure published
26 Nov 2025, 09:46 GMT - Award pending
Not published · £2,100,000
Commercial outcome and competition
Awards BRISTOL-MYERS SQUIBB PHARMACEUTICALS LIMITED £2,100,000 · Not published · pending |
ContractsNo contract published |
Bid statisticsNo aggregate bid statistics published |
Buyer and organisations in this procedure
Barts Health NHS Trust
Contracting authority GB-PPON-PVTL-5832-LMDGAward and contract changes
Documents (1)
Official links; attachments are not copied
Related procedures (0)
No related procedures published
Planning and rationale
Planning budgetNot published |
No-engagement rationaleNot published |
Procedure rationaleCAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a new personalised immunotherapy treatment where a patient’s T cells are genetically modified to target cancer cells.
The products can only be supplied by the the proposed contractor, Bristol Myers Squibb. |